Pfizer's (NYSE: PFE) share price has fallen more than the S&P 500 so far this year. If you're a growth investor, you probably ...

The drug is approved both to treat and prevent migraine in adults and is one of ... GlobalData said recently it expects Nurtec ODT to reach a peak of around $2 billion in annual sales in 2029 ...

Atogepant was approved last September as Qulipta for migraine prevention in the US – where Vydura is known as Nurtec ODT and was cleared for acute migraine treatment in early 2020 and for ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Although the company will lose patent exclusivity for several top drugs, it also has newer products on the market, such as cancer therapies Adcetris and Padcev along with migraine drug Nurtec ODT ...

The global brain biomarkers market is poised for remarkable growth, fueled by the escalating prevalence of neurological disorders and rapid technological advancements. A recent market analysis reveals ...

In mid-March here, I (Tom Yeung) wrote about three stocks to sell on an escalating trade war. President Donald Trump was ratcheting his tariff rhetoric, so we highlighted three import-reliant firms to ...

The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the ...